Stock Analiz

AbCellera Biologics Inc. (ABCL) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

AbCellera Biologics’s revenue went from $12M in fiscal 2019 to $75M in fiscal 2025, growth of about 36.5% a year.

Net income in fiscal 2025 was -$146M, a net margin of -194.9%; the best year in this period was 2022 with $159M.

Over the twelve months to September 30, 2026, revenue was $68M and net income -$148M.

Free cash flow was -$174M in fiscal 2025 and positive in 3 of the 7 years shown.

The diluted share count rose 97% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $12M20192020: $233M20202021: $375M20212022: $485M20222023: $38M20232024: $29M20242025: $75M2025$75M
Net income
2019: -$2M20192020: $119M20202021: $153M20212022: $159M20222023: -$146M20232024: -$163M20242025: -$146M2025-$146M
Free cash flow
2019: -$1M20192020: $13M20202021: $186M20212022: $207M20222023: -$121M20232024: -$187M20242025: -$174M2025-$174M
EPS (diluted)
2019: $-0.0120192020: $0.4520202021: $0.4820212022: $0.5020222023: $-0.5120232024: $-0.5520242025: $-0.492025$-0.49

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$68M$75M$29M$38M$485M$375M$233M$12M
Gross profit————————
Operating income-$202M-$217M-$315M-$237M$217M$204M$156M-$4M
Net income-$148M-$146M-$163M-$146M$159M$153M$119M-$2M
EPS (diluted)$-0.48$-0.49$-0.55$-0.51$0.50$0.48$0.45$-0.01
R&D$186M$187M$167M$176M$108M$62M$29M$10M
Revenue growth—+160.6%−24.2%−92.2%+29.4%+60.9%+1907.9%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$15M-$131M-$109M-$44M$277M$245M$23M$3M
Capital spending-$17M-$43M-$78M-$77M-$71M-$58M-$10M-$4M
Free cash flow-$33M-$174M-$187M-$121M$207M$186M$13M-$1M
Dividends paid—$0$0$0$0$0——
Buybacks————————
Stock-based pay$49M$56M$68M$64M$49M$31M$8M$890000

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$129M$156M$133M$387M$476M$594M—
Debt—$143M$65M$77M$82M$40M$4M—
Equity—$967M$1.1B$1.2B$1.2B$1.0B$831M$10M
Total assets—$1.4B$1.4B$1.5B$1.5B$1.3B$1.0B—
Shares (diluted)318M299M294M289M315M318M263M151M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin————————
Operating margin-298.0%-289.0%-1091.7%-623.8%44.6%54.5%66.9%-35.4%
Net margin-218.5%-194.9%-564.8%-385.0%32.7%40.9%51.0%-19.0%
FCF margin-48.4%-231.7%-648.4%-317.8%42.6%49.6%5.6%-11.2%
ROIC—-16.1%-22.8%-16.2%10.9%13.4%14.1%-31.7%
ROE—-15.1%-15.4%-12.7%12.8%15.0%14.3%-21.6%

Frequently asked questions

What is AbCellera Biologics’s annual revenue?

$75M in fiscal 2025 and $68M over the twelve months to September 30, 2026.

How much profit does AbCellera Biologics make?

Net income was -$146M in fiscal 2025 (net margin -194.9%).

Is AbCellera Biologics’s revenue growing?

Yes: revenue rose 160.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.